ABSTRACT
Rationale Identification and validation of circulating biomarkers for lung function decline in COPD remains an unmet need.
Objective Identify prognostic and dynamic plasma protein biomarkers of COPD progression.
Methods We measured plasma proteins using SomaScan from two COPD-enriched cohorts, the Subpopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS) and Genetic Epidemiology of COPD (COPDGene), and one population-based cohort, Multi-Ethnic Study of Atherosclerosis (MESA) Lung. Using SPIROMICS as a discovery cohort, linear mixed models identified baseline proteins that predicted future change in FEV1 (prognostic model) and proteins whose expression changed with change in lung function (dynamic model). Findings were replicated in COPDGene and MESA-Lung. Using the COPD-enriched cohorts, Gene Set Enrichment Analysis (GSEA) identified proteins shared between COPDGene and SPIROMICS. Metascape identified significant associated pathways.
Measurements and Main Results The prognostic model found 7 significant proteins in common (p < 0.05) among all 3 cohorts. After applying false discovery rate (adjusted p < 0.2), leptin remained significant in all three cohorts and growth hormone receptor remained significant in the two COPD cohorts. Elevated baseline levels of leptin and growth hormone receptor were associated with slower rate of decline in FEV1. Twelve proteins were nominally but not FDR significant in the dynamic model and all were distinct from the prognostic model. Metascape identified several immune related pathways unique to prognostic and dynamic proteins.
Conclusion We identified leptin as the most reproducible COPD progression biomarker. The difference between prognostic and dynamic proteins suggests disease activity signatures may be different from prognosis signatures.
Competing Interest Statement
KH, JL, EK, and MO are Novartis employees with stock options. MM is a former Novartis employee with stock options and is a current Bristol Myers Squibb employee with stock options. IZB reports grant funding from Theravance & Viatris, Aerogen and Takeda and consulting fees from Astra Zeneca, Sanofi/Regeneron, Grifols, Verona Pharma, Inhibrx and Takeda. APC reports being a non-paid consultant for VIDA. CBC reports personal fees Cambridge University Press, GlaxoSmithKline, Chulalongkorn University in Bangkok; payment for expert testimony from various law firms; personal and/or participation on advisory boards with NUVAIRA, Horizon Therapeutics, MGC Diagnostics, Chiesi, Herbalife Nutrition Institute, Respiree, Aer Therapeutics, Genetec, RS Biotherapeutics, Verona and support for attending EU investigator meetings from AstraZeneca. MKH reports grant support from NIH, Sanofi, Novartis, NUVAIRA, Sunovion, Gala Therapeutics, COPD Foundation, AstraZeneca, American Lung Association, Boehringer Ingelheim, Biodesix; royalties from UpToDate, Norton Publishing, Penguin Random House; consulting fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pulmonx, Teva, Verona, Merck, Mylan, Sanofi, DevPro, Aerogen, Polarion, Regeneron, Altesa BioPharma, Amgen, Roche, United Therapeutics, RS biotherapeutics, Apreo Health; honoraria from Cipla, Chiesi, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Medscape, Integrity, NACE, Medwiz; stocks in Meissa Vaccines, Altesa BioPharma and has received writing support from GSK, Boehringer Ingelheim, AstraZeneca, and Novartis. She participates on a data safety monitoring board for Novartis and Medtronics with funds patient to the institution and holds leadership or fiduciary roles with the COPD Foundation Board, COPD foundation Scientific Advisory Committee, ALA advisory Committee and volunteer spokesperson, ATS journal editor, GOLD scientific committee and the Emerson School Board in Ann Arbor Michigan. NH received research grant support from Astra Zeneca, GSK, Sanofi, Genentech, Novartis and Teva; consulting fees from Sanofi, GSK, Amgen, TEVA, Astra Zeneca, Genentech, Verona Pharma and honoraria from Regeneron. CPH reports grant support from Alpha-1 foundation, Boehringer-Ingelheim, Bayer and Vertex and consulting fees from Chiesi, Sanofi and Takeda. WWL reports personal fees from Continuing Education Alliance. FJM reports consulted fees from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GSK, Novartis, Polarean, Pulmonx, Sanofi/Regeneron, Sunovion, TEVA, Theravance/Viatris, UpToDate; payment for a disease statant presentation from GSK and AstraZeneca; and grant support from AstraZeneca, Chiesi, GSK and Sanofi/Regeneron. WKO reports honoraria paid to participate in annual review for the CF foundations activities related to National Mouse Resource at CWRU, leadership/fiduciary role in CF foundation North America Conference Planning Committee and payments to review research grants from the NHLBI LCMI study section and CF foundation. PGW reports consulting fees from Sanofi, Regeneron, Roche and Astra Zeneca. JMW reports grants/contracts from ARCUS-Med, Mereo BioPharma, Medscape, Verona Pharma, Grifols, Alpha-1 Foundation, Inhibrx, Department of Veterans Affairs; personal fees for advisory work from AstraZeneca, Takeda, GSK, Bavarian Nordic; stock options from Alveolus Bio and support for medical writing from Takeda, GSK and Verona Pharma. JLC received consulting fees from AstraZeneca PLC, CSL Behring, LLC, and Novartis Corporation. NG is a Novartis employee with stock options.
Funding Statement
SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C), grants from the NIH/NHLBI (U01 HL137880, U24 HL141762, R01 HL182622, and R01 HL144718), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from Amgen; AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; Genentech; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; MGC Diagnostics; Novartis Pharmaceuticals Corporation; Nycomed GmbH; Polarean; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; and Theravance Biopharma and Mylan/Viatris. Proteomic sample profiling was funded by Novartis. COPDGene proteomics was supported by R01 HL137995. COPDGene was supported by Award Number U01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health; COPD Foundation Funding: The COPDGene project is also supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, and Sunovion. MESA-Lung was supported by R01-HL077612, R01-HL093081 and R01-HL130506, from the National Heart Lung and Blood Institute (NHLBI). MESA and the MESA SHARe projects were supported by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute, and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from the National Center for Advancing Translational Sciences (NCATS). DEG was funded by T32-HL144442.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
SPIROMICS was approved by Institutional Review Boards at all respective clinical sites (Johns Hopkins University, Columbia University, University of Utah, University of California San Diego, National Jewish Hospital, University of Alabama Birmingham, University of North Carolina, Wake Forest University, University of Michigan, Temple University, University of Illinois, University of Iowa and University of California Los Angeles). All participants provided written informed consent COPDGene was approved and reviewed by the institutional review board at all clinic sites [National Jewish IRB, Partners Human Research Committee, Institutional Review Board for Baylor College of Medicine and Affiliated Hospitals, Institutional Review Board for Baylor College of Medicine and Affiliated Hospitals, Columbia University Medical Center IRB, The Duke University Health System Institutional Review Board for Clinical Investigations (DUHS IRB), Johns Hopkins Medicine Institutional Review Boards (JHM IRB), The John F. Wolf, MD Human Subjects Committee of Harbor UCLA Medical Center, Morehouse School of Medicine Institutional Review Board, Temple University Office for Human Subjects Protections Institutional Review Board, The University of Alabama at Birmingham Institutional Review Board for Human Use, University of California, San Diego Human Research Protections Program, The University of Iowa Human Subjects Office, VA Ann Arbor Healthcare System IRB, University of Minnesota Research Subjects Protection Programs (RSPP), University of Pittsburgh Institutional Review Board, UT Health Science Center San Antonio Institutional Review Board, Health Partners Research Foundation Institutional Review Board, Medical School Institutional Review Board (IRBMED), Minneapolis VAMC IRB Institutional Review Board/Research Review Committee Saint Vincent Hospital Fallon Clinic Fallon Community Health Plan]. MESA was approved by the Institutional Review Boards of all MESA field centers, including Wake Forest University School of Medicine, University of Minnesota, Northwestern University, Columbia University, Johns Hopkins University, University of California, and the MESA Coordinating Center for the collection of the original data. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived for all 3 studies (SPIROMICS, COPDGene and MESA).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
